Guidance on patient Identification and Administration of Recombinant Human Activated protein C for the Treatment of Severe Sepsis

Simple item page
dc.contributor.authorGarber, Gary
dc.contributor.authorGibney, RT Noel
dc.contributor.authorLight, Bruce
dc.contributor.authorMartin, Claudio
dc.contributor.authorCunningham, Kenneth
dc.contributor.authorGuimond, Jean-Gilles
dc.contributor.authorMagder, Sheldon
dc.contributor.authorRussell, James
dc.date.accessioned2016-06-08T20:12:36Z
dc.date.available2016-06-08T20:12:36Z
dc.date.issued2002-1-1
dc.date.updated2016-06-07T07:00:45Z
dc.description.abstractApproximately one-third of cases of severe sepsis result in death. Endogenous activated protein C (ApC) plays a key role in the regulation of the inflammation, fibrinolysis and coagulation associated with severe sepsis. In a recently published phase III trial, protein C Worldwide Evaluation in Severe Sepsis (pROWESS), intravenous administration of recombinant human ApC (rhApC) 24 µg/kg/h for 96 h to patients with severe sepsis resulted in a 6.1% reduction in absolute mortality and a 19.4% reduction in the relative risk of death from any cause within 28 days (number needed to treat = 16). This dose is now being applied in clinical practice.rhApC is recommended for the treatment of severe sepsis (sepsis associated with acute organ dysfunction) occurring as a result of all types of infection (Gram-negative bacterial, Gram-positive bacterial and fungal). A panel of Canadian clinicians experienced in the treatment of severe sepsis and the management of critical care patients has developed this consensus document to assist clinicians in appropriate patient selection and management of potential challenges associated with rhApC therapy.
dc.description.versionPeer Reviewed
dc.identifier.citationGary Garber, RT Noel Gibney, Bruce Light, et al., “Guidance on patient Identification and Administration of Recombinant Human Activated protein C for the Treatment of Severe Sepsis,” Canadian Journal of Infectious Diseases, vol. 13, no. 6, pp. 361-372, 2002. doi:10.1155/2002/916317
dc.identifier.urihttp://dx.doi.org/10.1155/2002/916317
dc.identifier.urihttp://hdl.handle.net/1993/31431
dc.language.rfc3066en
dc.rightsopen accessen_US
dc.rights.holderCopyright © 2002 Hindawi publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.titleGuidance on patient Identification and Administration of Recombinant Human Activated protein C for the Treatment of Severe Sepsis
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
CJIDMM.2002.916317.xml
Size:
15.75 KB
Format:
Extensible Markup Language
Description:
Download
Thumbnail Image
Name:
CJIDMM.2002.916317.pdf
Size:
391.58 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.24 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
University of Manitoba Scholarship
Rady Faculty of Health Sciences Scholarly Works